New Search

If you are not happy with the results below please do another search

1383 search results for:

11

Tumour markers in lung cancer: modelling strategies for interpretation of tumour marker changes and potential clinical applications

By Dr F. van Delft, Dr M. Schuurbiers, Dr van den Heuvel and Dr H. van Rossum The development of immunotherapy and other targeted therapies has given rise to significant improvements in the treatment of non-small cell lung cancer. However, some patients do not benefit from these therapies and it is, therefore, important for a […]

12

The Man Van: catching prostate cancer early

We all know that detecting cancer early is the key to obtaining the best treatment outcomes. However, how do you do this when some sectors of the population struggle to access healthcare and does point-of care testing make it possible to take health screening to the people who need it? CLI caught up with Professor […]

13

Improving equity of diagnosis of ovarian cancer

Although the prevalence of ovarian cancer is fairly low, it is often asymptomatic until after metastasis, resulting in it being the fourth leading cause of cancer death in females in the USA. The development of biomarker screening tests for ovarian cancer has been challenging and the situation is still not satisfactory. Additionally, the tests that […]

15

Utility of human chorionic gonadotropin as a tumour marker

By Rosa Ferrer, Andrea Mansilla and Maria Costa The role of human chorionic gonadotropin in pregnancy has been extensively studied for many years. However, the importance of this hormone goes beyond pregnancy. It can also be used as a biomarker, mainly in trophoblastic tumours, but as will be shown later in this article, its importance […]

16

Take a 360° look at your medical biology practice at the JIB congress

Attend the Innovation Days in Biology (JIB) and stay connected to the scientific, technical, professional and organizational developments of medical biology. Medical biology is essential to the health of our fellow citizens, from diagnosis to treatment and follow-up, scientists are continually looking for innovation. There are many hot topics expected at the event in Paris […]

19

Immunohistochemical approaches for the molecular subtyping of bladder cancer

The subtyping of bladder cancers is a complicated business. It is, however, necessary as it has important implications for prognosis and therapeutic decisions. CLI caught up with Asst. Prof. Chelsea L. Jackson (University of Manitoba, Winnipeg, MB, Canada) and Prof. David Berman (Queen’s University, Kingston, ON, Canada) to find out more about how the current […]